About The Study: In this cohort study of individuals with regular menstrual cycles, influenza vaccine given alone or in combination with a COVID-19 vaccine was associated with a small but temporary change in menstrual cycle length. These findings may help clinicians confirm the utility of vaccination for patients with concerns about menstrual adverse effects of vaccination.

About The Study: Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients having ever received a prescription during that period. Furthermore, there were disparities in prescribing of varying magnitude based on race and ethnicity, social vulnerability, and urbanicity, although the absolute differences were small compared with the overall underutilization.

A harmful form of the tau protein, which builds up in Alzheimer’s disease and similar brain disorders, can directly damage blood vessels in the brain, according to a new study by researchers at the Lewis Katz School of Medicine at Temple University. It does this by changing how the cells lining the blood vessels produce energy, which leads to inflammation and makes the blood-brain barrier – the brain's protective shield – weaker.

The discovery, reported online in Alzheimer’s & Dementia, the journal of the Alzheimer’s Association, uncovers a novel molecular mechanism that potentially explains tau-mediated vascular dysfunction in the brain and highlights the importance of focusing on early neurovascular changes mediated by tau to help prevent or slow down damage to the blood-brain barrier in Alzheimer’s disease.

More Americans are beating cancer than ever, yet many still grapple with treatment’s long shadow — especially on their mental health.

A new Northwestern Medicine study found most head-and-neck cancer survivors who underwent radiation don’t know about “survivorship care,” even as many grapple with side effects such as lingering dry mouth, swallowing problems and psychological distress.

This Phase III trial is based on a Phase I trial of patients in which the engineered cells were shown to be safe and effective, with minimal side effects. Initial study results were published April 9 in the scientific journal Nature Medicine.